Is simplification of immunosuppressive medication a way to promote medication adherence of kidney transplant recipients? Findings from a randomized controlled trial.
Regina van ZantenAnnelies E de WeerdMichiel G H BetjesMarieken Boer-VerschragenEmma K MasseyPublished in: Transplant international : official journal of the European Society for Organ Transplantation (2021)
After kidney transplantation, a strict immunosuppressive medication regimen is necessary for graft survival. However, nonadherence to medication has been shown to occur early after transplantation and to increase over time. Weaning the recipient off dual therapy onto monotherapy in order to reduce immunosuppressive burden may also be a way to promote adherence, although little is known about the impact of such a regimen on fear of rejection. We performed a cohort study on medication adherence and fear of rejection in a randomized, investigator-driven, open-label, single-centre pilot study. Recipients were randomized at 6-months post-transplant to either continue Tacrolimus and Mycophenolate mofetil (TAC/MMF) or to taper MMF at 6 months and discontinue MMF at 9 months (TAC monotherapy). Recipients completed questionnaires about medication adherence and fear of rejection at 6 and 12-months post-transplantation. Medication adherence was significantly higher in the TAC monotherapy group compared to dual TAC/MMF therapy group (χ2 (1) = 4.582; P = 0.032). We found no difference in fear of rejection between the two groups of recipients (P = 0.887). Simplification of the medication regimen is a potential tool for increasing adherence in clinical practice (Netherlands Trial Register - NL4672).
Keyphrases
- open label
- phase iii
- phase ii
- clinical trial
- adverse drug
- study protocol
- healthcare
- prefrontal cortex
- clinical practice
- phase ii study
- combination therapy
- kidney transplantation
- randomized controlled trial
- emergency department
- double blind
- stem cells
- mesenchymal stem cells
- squamous cell carcinoma
- weight loss
- locally advanced
- skeletal muscle
- rectal cancer